Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes - PubMed (original) (raw)
Low levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes
P Pozzilli et al. Horm Metab Res. 2005 Nov.
Abstract
Background and aims: An epidemiological retrospective study and a recent prospective study from Finland have both concluded that vitamin D3 supplementation at birth protects individuals from type 1 diabetes later in life. Moreover, it is thought that vitamin D3 supplementation, in particular its activated form, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], may act as an immunomodulator, facilitating the shift from a Th1 to a Th2 immune response. The aim of this surveillance study was to measure levels of both 25-hydroxyvitamin D3 (25OHD3) and 1,25-dihydroxyvitamin D3 in patients with newly diagnosed type 1 diabetes as compared to normal subjects.
Methods: We measured plasma levels of 25-hydroxyvitamin D3 [25OHD3] and 1,25-dihydroxyvitamin D3 by radioimmunoassay in 88 consecutive patients with newly diagnosed type 1 diabetes (mean age 14.6 years; diagnosis within the last week), and in 57 healthy age and sex-matched subjects (mean age 16.5 years) born and residing in the Lazio region of continental Italy.
Results: Mean levels of both 25OHD3 and 1,25-(OH)2D3 were significantly lower in patients compared to controls (p < 0.01 and p < 0.03, respectively). There was no correlation between 1,25-(OH)2D3 plasma level and metabolic control status at disease diagnosis, age, gender, or most importantly, seasonality of disease diagnosis. This new observation endorses the findings of the Finnish study, even though Italy is a geographic area with more hours of sunlight than Finland.
Conclusions: These findings suggest that vitamin D3 may be an important pathogenic factor in type 1 diabetes independent of geographical latitude, and that its supplementation should be considered not only at birth, but also at diagnosis of type 1 diabetes with the aim of favouring a Th2 immune response and protecting residual beta cells from further destruction.
Similar articles
- Changes of vitamin D3 serum concentrations at the onset of immune-mediated type 1 (insulin-dependent) diabetes mellitus.
Baumgartl HJ, Standl E, Schmidt-Gayk H, Kolb HJ, Janka HU, Ziegler AG. Baumgartl HJ, et al. Diabetes Res. 1991 Mar;16(3):145-8. Diabetes Res. 1991. PMID: 1666347 - 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients.
Matias PJ, Ferreira C, Jorge C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A. Matias PJ, et al. Nephrol Dial Transplant. 2009 Feb;24(2):611-8. doi: 10.1093/ndt/gfn502. Epub 2008 Sep 4. Nephrol Dial Transplant. 2009. PMID: 18775809 - Inappropriate serum levels of retinol, alpha-tocopherol, 25 hydroxyvitamin D3 and 24,25 dihydroxyvitamin D3 levels in healthy Spanish adults: simultaneous assessment by HPLC.
Mata-Granados JM, Luque de Castro MD, Quesada Gomez JM. Mata-Granados JM, et al. Clin Biochem. 2008 Jun;41(9):676-80. doi: 10.1016/j.clinbiochem.2008.02.003. Epub 2008 Feb 15. Clin Biochem. 2008. PMID: 18313404 - [1,25-dihydroxyvitamin D3: the endocrine system meets the immune system].
Mathieu C, Decallonne B, van Etten E. Mathieu C, et al. Verh K Acad Geneeskd Belg. 2002;64(1):71-80; discussion 80-2. Verh K Acad Geneeskd Belg. 2002. PMID: 11995203 Review. Dutch.
Cited by
- Multifaceted Roles of Vitamin D for Diabetes: From Immunomodulatory Functions to Metabolic Regulations.
Park CY, Shin S, Han SN. Park CY, et al. Nutrients. 2024 Sep 20;16(18):3185. doi: 10.3390/nu16183185. Nutrients. 2024. PMID: 39339785 Free PMC article. Review. - Vitamin D efficacy in type 1 and type 2 diabetes.
Kawahara T, Okada Y, Tanaka Y. Kawahara T, et al. J Bone Miner Metab. 2024 Jul;42(4):438-446. doi: 10.1007/s00774-024-01509-3. Epub 2024 Apr 25. J Bone Miner Metab. 2024. PMID: 38664254 Review. - Differences in Plasma 25-Hydroxyvitamin D Levels at Diagnosis of Celiac Disease and Type 1 Diabetes.
Marino M, Galeazzi T, Gesuita R, Ricci S, Catassi C, Cherubini V, Lionetti E. Marino M, et al. Nutrients. 2024 Mar 5;16(5):743. doi: 10.3390/nu16050743. Nutrients. 2024. PMID: 38474871 Free PMC article. - PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes.
Penaforte-Saboia JG, Couri CEB, Albuquerque NV, Linard LLP, Araújo DAC, de Oliveira SKP, Gomes TFP, Pinheiro MM, Castelo MHCG, Fernandes VO, Montenegro Júnior RM. Penaforte-Saboia JG, et al. Diabetes Metab Syndr Obes. 2024 Feb 21;17:857-864. doi: 10.2147/DMSO.S437635. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38406268 Free PMC article. - Gene-environment interaction in the pathophysiology of type 1 diabetes.
Mittal R, Camick N, Lemos JRN, Hirani K. Mittal R, et al. Front Endocrinol (Lausanne). 2024 Jan 26;15:1335435. doi: 10.3389/fendo.2024.1335435. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38344660 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical